Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab

• Auteurs principaux: Lei Wang (Auteur), Lixiong Liu (Auteur), Xiaoping Hong (Auteur), Dongzhou Liu (Auteur), Zeneng Cheng (Auteur)
• Format: Livre
• Publié: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Delanzomib is a novel proteasome inhibitor initially developed for treating multiple myeloma. It was found to inhibit the expression of tumor necrosis factor alpha (TNF-α). This study aimed to investigate the ameliorating effect of delanzomib on collagen-induced arthritis (CIA) and to explore the ph...